Allogene Therapeutics ALLO Letters of Credit Outstanding, Amount
Letters of Credit Outstanding, Amount at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LettersOfCreditOutstandingAmount.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's letters of credit outstanding, amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's letters of credit outstanding, amount?
- Allogene Therapeutics (ALLO) reported letters of credit outstanding, amount of $6M in Q1 2026.
- How has Allogene Therapeutics's letters of credit outstanding, amount changed year-over-year?
- Allogene Therapeutics's letters of credit outstanding, amount decreased by 0.0% year-over-year, from $6M to $6M.
- What is the long-term trend for Allogene Therapeutics's letters of credit outstanding, amount?
- Over 5 years (2020 to 2025), Allogene Therapeutics's letters of credit outstanding, amount has grown at a 6.9% compound annual growth rate (CAGR), from $4.3M to $6M.